0001193125-20-037812.txt : 20200214 0001193125-20-037812.hdr.sgml : 20200214 20200214143908 ACCESSION NUMBER: 0001193125-20-037812 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20200214 DATE AS OF CHANGE: 20200214 GROUP MEMBERS: BIOTECH INVEST N.V. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: IONIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000874015 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330336973 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-41771 FILM NUMBER: 20618182 BUSINESS ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 BUSINESS PHONE: 7609319200 MAIL ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 FORMER COMPANY: FORMER CONFORMED NAME: ISIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BB BIOTECH AG CENTRAL INDEX KEY: 0000924223 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] IRS NUMBER: 000000000 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: SCHWERTSTRASSE 6 CITY: SCHAFFHAUSEN STATE: V8 ZIP: 8200 BUSINESS PHONE: 411724 59 59 MAIL ADDRESS: STREET 1: SCHWERTSTRASSE 6 CITY: SCHAFFHAUSEN STATE: V8 ZIP: 8200 SC 13G/A 1 d826488dsc13ga.htm SC 13G/A SC 13G/A

 

 

United States

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 9)*

 

 

IONIS PHARMACEUTICALS, INC.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

462222100

(CUSIP Number)

December 31, 2019

(Date of Event Which Requires Filing This Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 462222100

 

   1.     

Names of Reporting Persons

 

BB Biotech AG

   2.  

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)  ☒        (b)  ☐

 

   3.  

SEC Use Only

 

   4.  

Citizenship or Place of Organization

 

Switzerland

Number of 

Shares 

Beneficially 

Owned by 

Each 

Reporting 

Person 

with: 

     5.      

Sole Voting Power

 

0

    6.   

Shared Voting Power

 

7,994,955

    7.   

Sole Dispositive Power

 

0

    8.   

Shared Dispositive Power

 

7,994,955

   9.     

Aggregate Amount Beneficially Owned by Each Reporting Person

 

7,994,955

 10.  

Check if the Aggregate Amount in Row (9) Excludes Certain Shares  ☐

 

 11.  

Percent of Class Represented by amount in Row (9)

 

5.7%

 12.  

Type of Reporting Person (See Instructions)

 

HC,CO

 

2 of 6

CUSIP No. 462222100

 

   1.     

Names of Reporting Persons

 

Biotech Invest N.V.1

 

I.R.S. Identification Nos. of above persons (entities only):

 

N/A

   2.  

Check the Appropriate Box if a Member of a Group (See Instructions)

(a)  ☒        (b)  ☐

 

   3.  

SEC Use Only

 

   4.  

Citizenship or Place of Organization

 

Curacao

Number of 

Shares 

Beneficially 

Owned by 

Each 

Reporting 

Person 

with: 

     5.      

Sole Voting Power

 

0

    6.   

Shared Voting Power

 

7,994,955

    7.   

Sole Dispositive Power

 

0

    8.   

Shared Dispositive Power

 

7,994,955

   9.     

Aggregate Amount Beneficially Owned by Each Reporting Person

 

7,994,955

 10.  

Check if the Aggregate Amount in Row (9) Excludes Certain Shares  ☐

 

 11.  

Percent of Class Represented by amount in Row (9)

 

5.7%

 12.  

Type of Reporting Person (See Instructions)

 

CO

 

1 

Pursuant to an internal restructuring the shares of Ionis Pharmaceuticals, Inc., which were previously held by Biotech Target N.V., have been transferred to Biotech Invest N.V.

 

3 of 6

Item 1

 

  1(a)

Name of Issuer: Ionis Pharmaceuticals, Inc.

 

  1(b)

Address of Issuer’s Principal Executive Offices:

2855 Gazelle Court, Carlsbad, California

Item 2

2(a) Name of Person Filing: BB Biotech AG (“BB Biotech”) on behalf of its wholly-owned subsidiary, Biotech Invest N.V. (“Biotech Invest”)

 

  2(b)

Address of Principal Business Office or, if none, Residence:

BB Biotech AG: Schwertstrasse 6, CH-8200 Schaffhausen, Switzerland

Biotech Invest N.V.: Ara Hill Top Building, Unit A-5, Pletterijweg Oost 1, Curaçao

 

  2(c)

Citizenship: BB Biotech AG: Switzerland

  Biotech Invest N.V.: Curacao

 

  2(d)

Title of Class of Securities Common Stock, $0.001 Par Value

 

  2(e)

CUSIP Number 462222100

Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

  (a)

Amount beneficially owned: 7,994,955

 

  (b)

Percent of class: 5.7%

 

  (c)

Number of shares as to which the person has:

 

  (i)

Sole power to vote or to direct the vote 0

 

  (ii)

Shared power to vote or to direct the vote 7,994,955

 

  (iii)

Sole power to dispose or to direct the disposition of 0

 

  (iv)

Shared power to dispose or to direct the disposition of 7,994,955

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

This statement is filed jointly by BB Biotech and Biotech Invest, Biotech Invest is a wholly-owned subsidiary of BB Biotech.

 

4 of 6

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURES

After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BB Biotech AG

 

Date: February 13, 2020     By:   /s/ Martin Gubler
      Signatory Authority
    Name:   Martin Gubler
    Title:   Signatory Authority
Date: February 13, 2020     By:   /s/ Ivo Betschart
      Signatory Authority
    Name:   Ivo Betschart
    Title:   Signatory Authority

Biotech Invest N.V.

 

Date: February 13, 2020     By:   /s/ Jan Bootsma
      Signatory Authority
    Name:   Jan Bootsma
    Title:   Signatory Authority
Date: February 13, 2020     By:   /s/ Hugo van Neutegem
      Signatory Authority
    Name:   Hugo van Neutegem
    Title:   Signatory Authority

 

5 of 6

Exhibit A

Joint Filing Statement

We, the undersigned, hereby express our agreement that the attached Schedule 13G (including all amendments thereto) is filed on behalf of each of the undersigned.

BB Biotech AG

 

Date: February 13, 2020     By:   /s/ Martin Gubler
      Signatory Authority
    Name:   Martin Gubler
    Title:   Signatory Authority
Date: February 13, 2020     By:   /s/ Ivo Betschart
      Signatory Authority
    Name:   Ivo Betschart
    Title:   Signatory Authority

Biotech Invest N.V.

 

Date: February 13, 2020     By:   /s/ Jan Bootsma
      Signatory Authority
    Name:   Jan Bootsma
    Title:   Signatory Authority
Date: February 13, 2020     By:   /s/ Hugo van Neutegem
      Signatory Authority
    Name:   Hugo van Neutegem
    Title:   Signatory Authority

 

6 of 6